1523-4681/asset/olbannerleft.gif?v=1&s=d7e4c0e37904a489128d3a4e58ba94214db307a9)
1523-4681/asset/olbannerright.gif?v=1&s=854ee0e4d351ead9faaca8bfab3e50b1c7c9d03d)
Original Article
You have full text access to this OnlineOpen article
IKKβ activation is sufficient for RANK-independent osteoclast differentiation and osteolysis
Article first published online: 1 FEB 2010
DOI: 10.1002/jbmr.4
Copyright © 2010 American Society for Bone and Mineral Research
Additional Information
How to Cite
Otero, J. E., Dai, S., Alhawagri, M. A., Darwech, I. and Abu-Amer, Y. (2010), IKKβ activation is sufficient for RANK-independent osteoclast differentiation and osteolysis. J Bone Miner Res, 25: 1282–1294. doi: 10.1002/jbmr.4
Publication History
- Issue published online: 27 MAY 2010
- Article first published online: 1 FEB 2010
- Accepted manuscript online: 1 FEB 2010 12:00AM EST
- Manuscript Accepted: 15 DEC 2009
- Manuscript Revised: 5 NOV 2009
- Manuscript Received: 6 JUL 2009
References
- 1. Osteoclasts: what do they do and how do they do it? Amer J Pathol. 2007; 170: 427–435.
- 2
- 3, . Genetic regulation of osteoclast development and function. Nat Rev Genet. 2003; 4: 638–649.
- 4. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med (Berlin, Germany). 2005; 83: 170–179.
- 5, , , et al. The tyrosine kinase activity of c-Src regulates actin dynamics and organization of podosomes in osteoclasts. Mol Biol Cell. 2008; 19: 394–404.
- 6, , , et al. Mice lacking β3-integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest. 2000; 105: 433–440.
- 7, , , et al. Syk, c-Src, the αvβ3-integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol. 2007; 176: 877–888.
- 8, , , , . DAP12 couples c-Fms activation to the osteoclast cytoskeleton by recruitment of Syk. Mol cell. 2008; 31: 422–431.
- 9, , , , , . Identifying the relative contributions of Rac1 and Rac2 to osteoclastogenesis. J Bone Min Res. 2008; 23: 260–270.Direct Link:
- 10. Bone resorption by osteoclasts. Science (New York). 2000; 289: 1504–1508.
- 11, , , , , . Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med. 1997; 3: 1285–1289.
- 12, , , , , . RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. J Clin Invest. 2008; 118: 2088–2097.
- 13, , , et al. RelB is the NF-κB subunit downstream of NIK responsible for osteoclast differentiation. Proc Natl Acad Sci USA. 2008; 105: 3897–3902.
- 14
- 15, . Regulation and function of IKK and IKK-related kinases. Science's STKE. 2006; 2006: re13.
- 16, , , et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature. 2000; 403: 103–118.
- 17, , , . The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem. 2004; 279: 37219–37222.
- 18, , , et al. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med. 2004; 10: 617–624.
- 19, , , et al. Osteoclast differentiation is impaired in the absence of IκB kinase-α. J Biol Chem. 2004; 279: 54841–54848.
- 20, , , et al. IκB kinase-β, but not IκK-α, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J. Exp. Med. 2005; 201: 1677–1687.
- 21, , , et al. Defective osteoclastogenesis by IKKβ null precursors is a result of receptor activator of NF-κB ligand (RANKL)-induced JNK-dependent apoptosis and impaired differentiation. J Biol Chem. 2008; 283: 24546–24553.
- 22, , , , , . Transgenic mice that express Cre recombinase in osteoclasts. Genesis (New York, N.Y.: 2000). 2004; 39: 178–185.
- 23, , , et al. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature. 2002; 417: 861–866.
- 24, , , et al. Osteoclast differentiation is impaired in the absence of IkB kinase-α. J Biol Chem. 2004; 279: 54841–54848.
- 25, , , et al. RelB is the NF-κB subunit downstream of NIK responsible for osteoclast differentiation. Proc Natl Acad Sci (USA). 2008; 105: 3897–3902.
- 26, , , et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci (USA). 1999; 96: 3540–3545.
- 27, , , et al. NF-κB p50 and p52 regulate receptor activator of NF-κB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem. 2007; 282: 18245–18253.
- 28, , , et al. IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science (New York, N.Y.). 1997; 278: 860–866.
- 29, , , . Positive and negative regulation of IκB kinase activity through IKKβ subunit phosphorylation. Science (New York, N.Y.). 1999; 284: 309–313.
- 30, , . Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene therapy. 2000; 7: 1063–1066.
- 31, , , , . A simple method for the rapid generation of recombinant adenovirus vectors. Gene therapy. 2000; 7: 1034–1038.
- 32, , , et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science (New York, N.Y.). 1994; 266: 443–448.
- 33, , , et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A. 1998; 95: 13453–13458.
- 34. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001; 142: 5050–5055.
- 35, , , et al. Severe liver degeneration and lack of NF-κB activation in NEMO/IKKgamma-deficient mice. Genes & development. 2000; 14: 854–862.
- 36, , . Characterization of the IκB-kinase NEMO binding domain. J Biol Chem. 2002; 277: 45992–46000.
- 37, . Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 1995; 9: 576–596.
- 38, , , et al. Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science. 2001; 293: 1495–1499.
- 39, , , et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002; 3: 889–901.
- 40, . The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004; 25: 280–288.
- 41, , , , , . Tumor necrosis factor superfamily cytokines and the pathogenesis of inflammatory osteolysis. Ann Rheu Dis. 2002; 61: 82–83.
- 42, , , , . IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest. 2005; 115: 282–290.
- 43, , , et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med. 2005; 202: 589–595.
- 44, , , et al. Sporadic hyperphosphatasia syndrome featuring periostitis and accelerated skeletal turnover without receptor activator of nuclear factor-κB, osteoprotegerin, or sequestosome-1 gene defects. J Clin Endo Metab. 2007; 92: 1897–1901.